Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Mar 13, 2003
HEMISPHERX TO HOST CONFERENCE CALL ON TUESDAY, MARCH 18, 2003 AT 11:00AM EST
Mar 12, 2003
HEMISPHERX ACQUIRES RIGHTS FOR THE ONLY FDA APPROVED NATURAL ALPHA INTERFERON DRUG Company Completes a $5,500,000 Private Placement Conference Call to be Held On Tuesday, March 18, 2003 at 11:00am EST
Mar 06, 2003
Hemispherx Biopharma to Present New Interim Clinical Data Regarding Phase IIB Study in HIV/AIDS at the 16th International Conference on Antiviral Research
Feb 12, 2003
Expanded Clinical Data on AmpligenÒ in HIV Disease to be presented at the 16th International Conference on Antiviral Research
Jan 31, 2003
Hemispherx Presents New Data on Long-term, Post-trial Effects of RNA-based Ampligen(R) for Treatment for Chronic Fatigue Syndrome
Jan 24, 2003
HEMISPHERX ANNOUNCES TAGLICH BROTHERS RELEASE OF UPDATED RESEARCH REPORT
Jan 22, 2003
REBROADCAST OF HEMISPHERX'S JANUARY 21, 2003 CONFERENCE CALL AVAILABLE ON COMPANY'S WEBSITE OR VIA TELEPHONE REPLAY
Jan 17, 2003
HEMISPHERX SCHEDULES CONFERENCE CALL TO REVIEW RECENT DEVELOPMENTS IN CLINICAL TRIAL EXPANSION, STRATEGIC PARTNERSHIP SUPPORT, FUNDING AND THE OVERALL COMMERCIALIZATION PROCESS
Jan 15, 2003
OFFUTT SECURITIES UPDATES INDEPENDENT RESEARCH COVERAGE ON HEMISPHERX BIOPHARMA, INC.
Jan 15, 2003
HEMISPHERX FILES WITH REGULATORS TO REGISTER 5 MILLION SHARES OF STOCK TO SUPPORT CLINICAL TRIAL EXPANSION
72
73
74
75
76
77
78
79
80
81
82
<<
<
>
>>
Privacy